Referências

Os dois textos da atividade Doença ou construto? e as fontes citadas no debate e nos comentários das questões.

Agência Nacional de Vigilância Sanitária. 2026. Resolução da Diretoria Colegiada RDC nº 1.036, de 9 de julho de 2026: atualização do Anexo I da Portaria SVS/MS nº 344/1998. https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias.

Agnew-Blais, Jessica C., Guilherme V. Polanczyk, Andrea Danese, Jasmin Wertz, Terrie E. Moffitt, e Louise Arseneault. 2016. “Evaluation of the Persistence, Remission, and Emergence of Attention-Deficit/Hyperactivity Disorder in Young Adulthood”. JAMA Psychiatry 73 (7): 713–20. https://doi.org/10.1001/jamapsychiatry.2016.0465.

American Psychiatric Association. 2013. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association. https://doi.org/10.1176/appi.books.9780890425596.

American Psychiatric Association. 2022. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishing. https://doi.org/10.1176/appi.books.9780890425787.

Ashinoff, Brandon K., e Ahmad Abu-Akel. 2021. “Hyperfocus: the forgotten frontier of attention”. Psychological Research 85 (1): 1–19. https://doi.org/10.1007/s00426-019-01245-8.

Barkley, Russell A. 1997. “Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD”. Psychological Bulletin 121 (1): 65–94. https://doi.org/10.1037/0033-2909.121.1.65.

Barkley, Russell A. et al. 2002. “International Consensus Statement on ADHD: January 2002”. Clinical Child and Family Psychology Review 5 (2): 89–111. https://doi.org/10.1023/A:1017494719205.

Barros, Denise Borges. 2014. “Os usos e sentidos do metilfenidato: experiências entre o tratamento e o aprimoramento da atenção”. Tese (Doutorado em Saúde Coletiva), Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro. http://www.bdtd.uerj.br/handle/1/4724.

Benson, Kari, Kate Flory, Kathryn L. Humphreys, e Steve S. Lee. 2015. “Misuse of stimulant medication among college students: a comprehensive review and meta-analysis”. Clinical Child and Family Psychology Review 18 (1): 50–76. https://doi.org/10.1007/s10567-014-0177-z.

Bradley, Charles. 1937. “The behavior of children receiving Benzedrine”. American Journal of Psychiatry 94 (3): 577–85. https://doi.org/10.1176/ajp.94.3.577.

Brasil. Ministério da Saúde. Secretaria de Vigilância Sanitária. 1998. Portaria nº 344, de 12 de maio de 1998: aprova o Regulamento Técnico sobre substâncias e medicamentos sujeitos a controle especial. Texto republicado no Diário Oficial da União de 1º de fevereiro de 1999. https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html.

Caye, Arthur, Thiago Botter-Maio Rocha, Luciana Anselmi, et al. 2016. “Attention-Deficit/Hyperactivity Disorder Trajectories From Childhood to Young Adulthood: Evidence From a Birth Cohort Supporting a Late-Onset Syndrome”. JAMA Psychiatry 73 (7): 705–12. https://doi.org/10.1001/jamapsychiatry.2016.0383.

Cooper, Miriam, Gemma Hammerton, Stephan Collishaw, et al. 2018. “Investigating late-onset ADHD: a population cohort investigation”. Journal of Child Psychology and Psychiatry 59 (10): 1105–13. https://doi.org/10.1111/jcpp.12911.

Crichton, Alexander. 2008. “An inquiry into the nature and origin of mental derangement: on attention and its diseases”. Journal of Attention Disorders 12 (3): 200–204. https://doi.org/10.1177/1087054708315137.

Crowe, Simon F., e Elizabeth K. Stranks. 2018. “The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis”. Archives of Clinical Neuropsychology 33 (7): 901–11. https://doi.org/10.1093/arclin/acx120.

Dalgalarrondo, Paulo. 2019. Psicopatologia e semiologia dos transtornos mentais. 3º ed. Artmed.

Demontis, Ditte, G. Bragi Walters, Georgios Athanasiadis, et al. 2023. “Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains”. Nature Genetics 55 (2): 198–208. https://doi.org/10.1038/s41588-022-01285-8.

Demontis, Ditte, Raymond K. Walters, Joanna Martin, et al. 2019. “Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder”. Nature Genetics 51 (1): 63–75. https://doi.org/10.1038/s41588-018-0269-7.

Faraone, Stephen V. 2018. “The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities”. Neuroscience and Biobehavioral Reviews 87: 255–70. https://doi.org/10.1016/j.neubiorev.2018.02.001.

Faraone, Stephen V., Tobias Banaschewski, David Coghill, et al. 2021. “The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder”. Neuroscience & Biobehavioral Reviews 128: 789–818. https://doi.org/10.1016/j.neubiorev.2021.01.022.

Faraone, Stephen V., Joseph Biederman, e Eric Mick. 2006. “The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies”. Psychological Medicine 36 (2): 159–65. https://doi.org/10.1017/S003329170500471X.

Kendell, R. E., J. E. Cooper, A. J. Gourlay, J. R. Copeland, L. Sharpe, e B. J. Gurland. 1971. “Diagnostic criteria of American and British psychiatrists”. Archives of General Psychiatry 25 (2): 123–30. https://doi.org/10.1001/archpsyc.1971.01750140027006.

Kessler, Ronald C., Lenard Adler, Minnie Ames, et al. 2005. “The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population”. Psychological Medicine 35 (2): 245–56. https://doi.org/10.1017/S0033291704002892.

Kollins, Scott H., Denton J. DeLoss, Elena Cañadas, et al. 2020. “A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial”. The Lancet Digital Health 2 (4): e168–78. https://doi.org/10.1016/S2589-7500(20)30017-0.

Lange, Klaus W., Susanne Reichl, Katharina M. Lange, Lara Tucha, e Oliver Tucha. 2010. “The history of attention deficit hyperactivity disorder”. ADHD Attention Deficit and Hyperactivity Disorders 2 (4): 241–55. https://doi.org/10.1007/s12402-010-0045-8.

Lim, Julian, e David F. Dinges. 2010. “A meta-analysis of the impact of short-term sleep deprivation on cognitive variables”. Psychological Bulletin 136 (3): 375–89. https://doi.org/10.1037/a0018883.

Mattos, Paulo, Maria Antonia Serra-Pinheiro, Luis Augusto Rohde, e Diana Pinto. 2006. “Apresentação de uma versão em português para uso no Brasil do instrumento MTA-SNAP-IV de avaliação de sintomas de transtorno do déficit de atenção/hiperatividade e sintomas de transtorno desafiador e de oposição”. Revista de Psiquiatria do Rio Grande do Sul 28 (3): 290–97. https://doi.org/10.1590/S0101-81082006000300008.

Mayes, Rick, e Adam Rafalovich. 2007. “Suffer the restless children: the evolution of ADHD and paediatric stimulant use, 1900–80”. History of Psychiatry 18 (72 Pt 4): 435–57. https://doi.org/10.1177/0957154X06075782.

Moffitt, Terrie E., Renate Houts, Philip Asherson, et al. 2015. “Is Adult ADHD a Childhood-Onset Neurodevelopmental Disorder? Evidence From a Four-Decade Longitudinal Cohort Study”. American Journal of Psychiatry 172 (10): 967–77. https://doi.org/10.1176/appi.ajp.2015.14101266.

Morton, W. Alexander, e Gwendolyn G. Stockton. 2000. “Methylphenidate abuse and psychiatric side effects”. Primary Care Companion to the Journal of Clinical Psychiatry 2 (5): 159–64. https://doi.org/10.4088/pcc.v02n0502.

Paelecke-Habermann, Yvonne, Johannes Pohl, e Bernd Leplow. 2005. “Attention and executive functions in remitted major depression patients”. Journal of Affective Disorders 89 (1–3): 125–35. https://doi.org/10.1016/j.jad.2005.09.006.

Panizzon, Leandro. 1944. “La preparazione di piridil- e piperidil-arilacetonitrili e di alcuni prodotti di trasformazione (Parte Iª)”. Helvetica Chimica Acta 27 (1): 1748–56. https://doi.org/10.1002/hlca.194402701222.

Pennick, Michael. 2010. “Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine”. Neuropsychiatric Disease and Treatment 6: 317–27. https://doi.org/10.2147/ndt.s9749.

Polanczyk, Guilherme V., Erik G. Willcutt, Giovanni A. Salum, Christian Kieling, e Luis A. Rohde. 2014. “ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis”. International Journal of Epidemiology 43 (2): 434–42. https://doi.org/10.1093/ije/dyt261.

Sharman, Johannah, e Michael Pennick. 2014. “Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells”. Neuropsychiatric Disease and Treatment 10: 2275–80. https://doi.org/10.2147/NDT.S70382.

Simons, Daniel J., e Christopher F. Chabris. 1999. “Gorillas in our midst: sustained inattentional blindness for dynamic events”. Perception 28 (9): 1059–74. https://doi.org/10.1068/p281059.

Still, George Frederic. 1902. “The Goulstonian lectures on some abnormal psychical conditions in children”. The Lancet 159 (4102): 1008–13. https://doi.org/10.1016/S0140-6736(01)74984-7.

Stroop, J. R. 1935. “Studies of interference in serial verbal reactions”. Journal of Experimental Psychology 18 (6): 643–62. https://doi.org/10.1037/h0054651.

Thomas, Rae, Sharon Sanders, Jenny Doust, Elaine Beller, e Paul Glasziou. 2015. “Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis”. Pediatrics 135 (4): e994–1001. https://doi.org/10.1542/peds.2014-3482.

Timimi, Sami, Joanna Moncrieff, Jon Jureidini, Jonathan Leo, David Cohen, et al. 2004. “A critique of the international consensus statement on ADHD”. Clinical Child and Family Psychology Review 7 (1): 59–63. https://doi.org/10.1023/B:CCFP.0000020192.49298.7a.

Timimi, Sami, e Eric Taylor. 2004. “ADHD is best understood as a cultural construct”. The British Journal of Psychiatry 184 (1): 8–9. https://doi.org/10.1192/bjp.184.1.8.

U.S. Food and Drug Administration. 2020a. De Novo classification request DEN200026: EndeavorRx. Carta de decisão, 15 de junho de 2020. https://www.accessdata.fda.gov/cdrh_docs/pdf20/DEN200026.pdf.

U.S. Food and Drug Administration. 2020b. FDA permits marketing of first game-based digital therapeutic to improve attention function in children with ADHD. Comunicado de imprensa, 15 de junho de 2020. http://web.archive.org/web/20250521055652/https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-game-based-digital-therapeutic-improve-attention-function-children-adhd.

Visser, Susanna N., Melissa L. Danielson, Rebecca H. Bitsko, et al. 2014. “Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011”. Journal of the American Academy of Child and Adolescent Psychiatry 53 (1): 34–46.e2. https://doi.org/10.1016/j.jaac.2013.09.001.

Westbrook, A., R. van den Bosch, J. I. Määttä, et al. 2020. “Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work”. Science 367 (6484): 1362–66. https://doi.org/10.1126/science.aaz5891.

World Health Organization. 2019. International Classification of Diseases, 11th Revision (ICD-11): 6A05 Attention deficit hyperactivity disorder. ICD-11 for Mortality and Morbidity Statistics. https://icd.who.int/browse/2024-01/mms/en#821852937.

World Health Organization. 2024. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. World Health Organization. https://www.who.int/publications/i/item/9789240077263.